Novartis Shows Importance Of Gene Therapy With AveXis Name Change
Swiss Major Renames AveXis As Novartis Gene Therapies
Novartis has completed its absorption of AveXis and rebranded the acquired gene therapy specialist that developed the soon-to-be SMA blockbuster Zolgensma despite struggling to meet the data integrity standards of regulators and big pharma.
You may also be interested in...
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.
The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.
The big pharma could not confirm whether AveXis co-founder and CSO Brian Kaspar and his brother, SVP of R&D Allan Kaspar, were fired. Instead, Novartis noted that the withholding of preclinical safety data for Zolgensma was limited to the action of a few employees. NIBR preclinical safety chief takes key role at AveXis